petemantx Wednesday, 09/13/17 09:04:12 AM Re:
Post# of 72440
Re: DrBones post# 196604
Post # of 196611
Over $100B spent on cancer research worldwide in 2015 and growing at nearly a 15% rate.
Is that sufficient reason for a BP to take a chance on a drug that appears to work safely, effectively, and is most likely near to having an oral delivery system?
I have to believe some BP will realize the upside with Kevetrin is so high that some serious dollars could be thrown it's way should the K (OC)results come in as strong as we expect.
Would also have to think by end of year we should be fairly close to a pill form being ready to test.
Lots of ifs and whatevers in the future facing K but it is definitely at a stage now where some BP should be ready to pony up some big bucks and become a partner IMO.
After all, this is the golden goose for revenues should K prove as complementary in working as a cancer cocktail as Dr M predicted.
I know you know all this, DrBones, but hope those being so short sighted on the now, now, now mantra for K realize how staggeringly massive is the market K is possibly going to impact.